Source: Pediatric Hematology and Oncology. Unidades: FMRP, FFCLRP
Subjects: ANTICORPOS MONOCLONAIS, HISTIOCITOSE, NEOPLASIAS POR TIPO HISTOLÓGICO
ABNT
VALERA, Elvis Terci et al. Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets?. Pediatric Hematology and Oncology. Abingdon: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1080/08880018.2020.1811438. Acesso em: 18 ago. 2024. , 2020APA
Valera, E. T., Brassesco, M. S., Reis, M. B. F. dos, Maggioni, G., Guerino-Cunha, R. L., Grecco, C. E., et al. (2020). Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? Pediatric Hematology and Oncology. Abingdon: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1080/08880018.2020.1811438NLM
Valera ET, Brassesco MS, Reis MBF dos, Maggioni G, Guerino-Cunha RL, Grecco CE, Elias Júnior J, Kato M, Tone LG. Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? [Internet]. Pediatric Hematology and Oncology. 2020 ; 38( 1): 89-96.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1080/08880018.2020.1811438Vancouver
Valera ET, Brassesco MS, Reis MBF dos, Maggioni G, Guerino-Cunha RL, Grecco CE, Elias Júnior J, Kato M, Tone LG. Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? [Internet]. Pediatric Hematology and Oncology. 2020 ; 38( 1): 89-96.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1080/08880018.2020.1811438